Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors

Department of Surgery II, Nagoya City University Medical School, Mizuho-ku, Nagoya 467-8601, Japan.
Japanese Journal of Clinical Oncology (Impact Factor: 1.75). 07/2006; 36(6):351-6. DOI: 10.1093/jjco/hyl028
Source: PubMed

ABSTRACT Epidermal growth factor receptor (EGFR) gene mutations have been reported to correlate with the sensitivity to the tyrosine kinase inhibitor treatment for advanced lung cancers. Since several reports have shown that invasive thymoma overexpress the EGFR protein, we examined the EGFR expression and mutation statuses in thymoma and thymic carcinoma tissues.
EGFR mutation statuses from 99 thymic epithelial tumor samples were evaluated by a rapid and sensitive TaqMan assay using Applied Biosysytems 7500 real-time PCR system. Probes were designed according to the 13 different EGFR mutations reported previously in lung cancers. A total of 38 thymoma samples were directly sequenced for the EGFR gene. Protein expressions were evaluated for 56 thymic epithelial tumors by immunohistochemistry.
EGFR gene mutations were not detected in any of the thymoma and thymic cancer samples using TaqMan PCR assay. Of the 38 samples 3 showed a heterozygous silent mutation without changes in the protein, a G to A transition at the nucleotide 2361 in exon 18. EGFR expression was significantly higher in invasive thymomas (stages III-IV, 15/19 were positive) than in early stage thymomas (stages I-II, 7/33 were positive) (P < 0.0001). All four carcinomas and all seven B3 thymomas showed EGFR positive staining.
Although EGFR mutation at the tyrosine kinase domain is unlikely to be a therapeutic target for thymoma, the information about EGFR expression would contribute to the further identification of the therapeutic target for advanced thymomas.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Characterization of the molecular alterations in thymic epithelial tumors may lead to a better understanding of tumorigenesis, new therapeutic targets, and biomarkers in these tumors.Material and methods: Paired tissue (tumor and matched normal) from 15 thymic carcinomas (TCA) and 6 B3 thymomas were evaluated by exon capture of 275 cancer related genes, followed by deep coverage next-generation sequencing, which can identifies somatic sequence variants, small insertions and deletions, and copy number alterations involving all exons of the captured genes.
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10/2014; DOI:10.1097/JTO.0000000000000397 · 5.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The rapid advent of technology in recent years has resulted in a substantial increase in our knowledge of the molecular underpinnings of thymic epithelial tumors. In addition to previously described chromosomal aberrations and alterations in DNA methylation, genome sequencing has helped unravel hitherto unknown mutations in these tumors. Attempts are also being made to develop gene signatures to help in the identification of patients likely to benefit from adjuvant therapy. Some of the recently identified genetic alterations have the potential to serve as targets for biological therapy, thus opening newer avenues for treatment of thymic epithelial tumors and increasing the number of effective options for treatment of recurrent or refractory disease.
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 09/2014; 9(9 Suppl 2):S131-S136. DOI:10.1097/JTO.0000000000000298 · 5.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Thymic carcinoma is a rare mediastinal neoplasm and little is known about its tumorigenesis. There is no effective treatment except for complete resection, and the prognosis of advanced cases is poor. To identify the mutations associated with tumorigenesis, we analyzed genetic profile of thymic carcinoma using targeted Next-Generation Sequencing. Materials and Methods We sequenced about 409 cancer related genes in 12 thymic squamous cell carcinoma tissues including 10 tumor/normal tissue pairs using Ion AmpliSeq Cancer Panel and Ion PGM Sequencer. We filtered the mutations with Ingenuity Variant Analysis, SIFT, PolyPhen-2, and PROVEAN. Results and Conclusion Twenty five candidate mutations in 24 genes were identified, including six tyrosine kinase genes (KIT, DDR2, PDGFRA, ROS1, IGF1R). There was no recurrent mutation among the samples studied. The KIT exon 11 deletion mutation in 1 patient was an activating mutation and may be an oncogenic driver mutation. Genetic profiling of thymic carcinoma using targeted next-generation sequencing was performed. The mutation status of thymic squamous cell carcinoma is highly heterogeneous.
    Lung Cancer 09/2014; 86(2). DOI:10.1016/j.lungcan.2014.08.020 · 3.74 Impact Factor